These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15920551)
1. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Rassidakis GZ; Thomaides A; Atwell C; Ford R; Jones D; Claret FX; Medeiros LJ Mod Pathol; 2005 Oct; 18(10):1365-70. PubMed ID: 15920551 [TBL] [Abstract][Full Text] [Related]
2. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487 [TBL] [Abstract][Full Text] [Related]
3. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813 [TBL] [Abstract][Full Text] [Related]
4. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928 [TBL] [Abstract][Full Text] [Related]
5. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631 [TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Watanabe M; Ogawa Y; Itoh K; Koiwa T; Kadin ME; Watanabe T; Okayasu I; Higashihara M; Horie R Lab Invest; 2008 Jan; 88(1):48-57. PubMed ID: 17965727 [TBL] [Abstract][Full Text] [Related]
7. Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Watanabe M; Itoh K; Togano T; Kadin ME; Watanabe T; Higashihara M; Horie R Am J Pathol; 2012 Feb; 180(2):831-8. PubMed ID: 22107829 [TBL] [Abstract][Full Text] [Related]
8. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Rodig SJ; Savage KJ; Nguyen V; Pinkus GS; Shipp MA; Aster JC; Kutok JL Am J Surg Pathol; 2005 Feb; 29(2):196-203. PubMed ID: 15644776 [TBL] [Abstract][Full Text] [Related]
10. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Mao X; Orchard G; Russell-Jones R; Whittaker S Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669 [TBL] [Abstract][Full Text] [Related]
11. CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas. Carminato A; Tecilla M; Roccabianca P; Zanardello C; Melchiotti E; Capello K; Vascellari M Vet Pathol; 2020 Jan; 57(1):49-55. PubMed ID: 31640480 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. Carbone A; Gloghini A; Volpe R Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287 [TBL] [Abstract][Full Text] [Related]
13. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils. Cepeda LT; Pieretti M; Chapman SF; Horenstein MG Am J Surg Pathol; 2003 Jul; 27(7):912-8. PubMed ID: 12826883 [TBL] [Abstract][Full Text] [Related]
14. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293 [TBL] [Abstract][Full Text] [Related]
15. [Lymphomatoid papulosis and anaplastic giant-cell lymphoma]. Moreau-Cabarrot A; Bonafé JL; Gorguet B; Andrieu H; Massip P Ann Dermatol Venereol; 1994; 121(10):727-30. PubMed ID: 7793765 [TBL] [Abstract][Full Text] [Related]
16. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414 [TBL] [Abstract][Full Text] [Related]
17. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433 [TBL] [Abstract][Full Text] [Related]
18. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment. Rinaldi I Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526 [TBL] [Abstract][Full Text] [Related]
19. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362 [TBL] [Abstract][Full Text] [Related]
20. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Schwartz Z; Bowe RB; Coleman M; Magro CM Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]